BEAM THERAPEUTICS PRESENTS UPDATED CLINICAL DATA FROM THE PHASE 1/2 TRIAL OF BEAM-302 IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AT THE EUROPEAN RESPIRATORY SOCIETY (ERS) CONGRESS 2026

Reuters · 1d ago

Please log in to view news